Copyright
©The Author(s) 2017.
World J Hepatol. Apr 18, 2017; 9(11): 544-550
Published online Apr 18, 2017. doi: 10.4254/wjh.v9.i11.544
Published online Apr 18, 2017. doi: 10.4254/wjh.v9.i11.544
Table 3 Adverse events and laboratory abnormalities
| Event | Elderly patients, n = 56 | Non-elderly patients, n = 141 |
| Nasopharyngitis | 5 (8.9) | 6 (4.3) |
| Headache | 4 (7.1) | 9 (6.4) |
| Diarrhea | 3 (5.4) | 5 (3.5) |
| Pyrexia | 2 (3.6) | 12 (8.5) |
| Malaise | 7 (12.5) | 8 (5.7) |
| Anorexia | 6 (10.7) | 8 (5.7) |
| AST elevation | 15 (26.8) | 55 (39.0) |
| ALT elevation | 14 (25.0) | 54 (38.3) |
| Hb decrease | 8 (14.3) | 11 (7.8) |
| Total bilirubin increase | 2 (3.6) | 11 (7.8) |
| Creatinine increase | 8 (14.3) | 13 (9.2) |
- Citation: Tarao K, Tanaka K, Nozaki A, Sato A, Ishii T, Komatsu H, Ikeda T, Komatsu T, Matsushima S, Oshige K. Efficacy and safety of dual therapy with daclatasvir and asunaprevir in elderly patients. World J Hepatol 2017; 9(11): 544-550
- URL: https://www.wjgnet.com/1948-5182/full/v9/i11/544.htm
- DOI: https://dx.doi.org/10.4254/wjh.v9.i11.544